P0471 Prevalence and risk factors for gallstone and renal stone formation in patients with intestinal Behçet’s disease

Abstract Background The association between inflammatory bowel disease (IBD) and gallstone and renal stone formation has been established. However, few studies have investigated this association in patients with intestinal Behçet’s disease (BD).We aimed to examine the prevalence of gallstones and renal stones in patients with intestinal BD and identify potential risk factors. Methods We analyzed gallstone and renal stone occurrences in 553 patients diagnosed with intestinal BD who had undergonecross-sectional imaging examinations between March 2005 and April 2021 at the IBD Center, Severance Hospital,Seoul, South Korea. Logistic regression models were used to identify risk factors for gallstone and renal stone formation. Results Of 553 patients over a mean 12.1-year duration, 141 (25.4%) patients had gallstones and 35 (6.3%) had renal stones. In multivariate logistic regression analysis, disease duration > 19 years (OR 2.91, 95% CI 1.56–5.44, p < 0.001), prior intestinal BD-related surgery (OR 2.29, 95% CI 1.42–3.68, p < 0.001), and disease activity index for intestinal BD scores ≥ 75(OR 2.23, 95% CI 1.12–4.45, p = 0.022) were associated with increased gallstone occurrence. A positive correlation was observed between renal stones, disease duration > 19 years (OR 5.61, 95% CI 1.98–15.90, p = 0.001) and frequent hospitalization(> 3 times) (OR 3.29, 95% CI 1.52–7.13, p = 0.002). No significant correlation was observed between gallstone and renal stone occurrence. Conclusion These findings contribute to greater understanding concerning gallstone and renal stone prevalence and associated risk factors in patients with intestinal BD. References 1.Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. NEngl J Med 1999;341:1284-1291. 2.Kaklamani VG, Kaklamanis PG. Treatment of Behçet’s disease--an update. Semin Arthritis Rheum 2001;30:299-312. 3.Kim DH, Cheon JH. Intestinal Behçet’s disease: a true inflammatorybowel disease or merely an intestinal complication ofsystemic vasculitis? Yonsei Med J 2016;57:22-32. 4.Suzuki Y, Hagiwara T, Kobayashi M, Morita K, Shimamoto T,Hibi T. Long-term safety and effectiveness of adalimumab in462 patients with intestinal Behçet’s disease: results from alarge real-world observational study. Intest Res 2021;19:301-312. 5.Song EM, Yang SK. Natural history of inflammatory boweldisease: a comparison between the East and the West. IntestRes 2022;20:418-430.